In this present study, the median PFS and OS of EGFR mutated NSCLC patients with solitary BM treated with EGFR-TKIs (SUR + TKI group and RT + TKI group) was 13.1 and 20.4 months, respectively, which is similar to previous researches. Here, EGFR is linked to non-small cell lung carcinoma.